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Abstract We recently proposed that the transient receptor
potential melastatin 5 (TRPM5) cation channel contributes
to glucose-induced electrical activity of the β cell and posi-
tively influences glucose-induced insulin release and glucose
homeostasis. In this study, we investigated Trpm5 expression
and function in pancreatic islets frommouse models of type II
diabetes. Gene expression analysis revealed a strong reduction
of Trpm5 mRNA levels in pancreatic islets of db /db and
ob /ob mice. The glucose-induced Ca2+ oscillation pattern in
db /db and ob /ob islets mimicked those of Trpm5−/− islets.
Leptin treatment of ob /ob mice not only reversed the diabetic
phenotype seen in these mice but also upregulated Trpm5
expression. Leptin treatment had no additional effect on
Trpm5 expression levels when plasma insulin levels were
comparable to those of the vehicle-injected control group. In
murine β cell line, MIN6, insulin downregulated TRPM5
expression in a dose-dependent manner, unlike glucose or
leptin. In conclusion, our data show that increased plasma
insulin levels downregulate TRPM5 expression in pancreatic
islets from leptin-deficient mouse models of type 2 diabetes.
Keywords Diabetes type 2 . TRPM5 . ob/obmice .
db/dbmice .MIN6 cells
Introduction
Diabetes type 2 mainly results from a combination of lifestyle
factors (such as obesity, sedentary lifestyle, unhealthy eating
habits…) and genetics. Moreover, environmental factors prob-
ably influence gene expression in almost all cells, including β
cells. This can have an effect on the susceptibility to disrup-
tions in glucose homeostasis and metabolic regulation and on
the risk profile for diabetes type 2 [9, 19, 35]. It has been
proposed that individuals at risk of diabetes type 2 carry one or
more polymorphisms in genes encoding ion channels or in
genes that regulate ion channel function, membrane targeting,
or expression [2]. As a result, such genetic backgroundswill be
reflected in small changes in β cell electrical activity that will
immediately be mirrored by changes in insulin secretion. Thus,
knowledge of the biophysical basis of insulin secretion and
glucose-induced electrical activity and identification of ion
channels with altered activity in type 2 diabetes is of great
clinical significance in the diagnosis and treatment of this
disease. Previous studies from our laboratory indicated the
transient receptor potential melastatin 5 (TRPM5) as an impor-
tant player in the electrical activity from theβ cell and glucose-
induced insulin release [6]. TRPM5 is a member of the large
family of TRP channels [10, 27], a group of cation channels
with diverse expression patterns that are shown to be important
in human diseases [10, 22, 23, 27] and suggested to have
significant roles in the pancreatic β cell [7]. TRPM5 is a
nonselective monovalent cation channel that is impermeable
to Ca2+ but directly activated by intracellular Ca2+ [11, 30].
The channel contributes to membrane depolarization during
electrically silent intervals, thereby facilitating the initiation of
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a new burst of activity. As a result, islets of Trpm5 knockout
(Trpm5−/−) mice show mainly slow glucose-induced changes
in membrane potential (Vm) and oscillations of the intracellular
Ca2+ concentration ([Ca2+]i), whereas islets of wild type (WT)
mice are characterized by fast, slow, andmixed oscillations [6].
Accordingly, Trpm5−/− islets release less insulin and Trpm5−/−
mice display lower plasma insulin levels andmoderate glucose
intolerance [3, 6]. This pre-diabetic phenotype in Trpm5−/−
mice suggests that TRPM5 might be a candidate for predispo-
sition of type 2 diabetes. Interestingly, genetic variation within
the Trpm5 locus is shown to associate with pre-diabetic phe-
notypes in subjects at increased risk for type 2 diabetes [13].
Two widely studied genetic models of type 2 diabetes are the
leptin receptor-deficient db /db and the leptin-deficient ob /ob
mouse, which develop morbid obesity due to impaired leptin
signaling and the characteristic hyperinsulinemia and hyper-
glycemia of type 2 diabetes [4, 5, 18]. We detected loss of
Trpm5 expression levels in the pancreatic islets of these mouse
models, which could be rescued by recovery of the leptin
pathway and the diabetic phenotype. Our data indicate that
high insulin levels are important in downregulation of Trpm5
in mouse models with impaired leptin signaling.
Research design and methods
Mice
All animal work was conducted following the ethical approval
of the KU Leuven Ethical Committee and according to national
and international guidelines. Db /db , ob /ob mice, and control
mice in C57BL/6J background were obtained from The
Jackson Laboratory. Only male mice were used for experi-
ments. Chow was purchased from Ssniff Spezialdiäten GmbH
(Germany). The high glucose chow contained ≥50 % glucose
and ≥12+ oligosaccharides/dextrines, whereas the high fat
chow contained 30.2 % crude fat. All other animals received
normal chow (containing 4.7 % sugar and 3.3 % crude fat).
Preparation of islets
Islets were isolated from male mice via collagenase digestion
as described previously [6]. The isolated islets were either
immediately used (RNA extraction) or cultured overnight
(Ca2+ imaging and incubation experiments) in islet culture
medium (advanced RPMI medium 1640 supplemented with
10 % FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, and
4 mM Glutamax) at 5 % CO2/95 % O2.
Glucose tolerance tests, plasma glucose, and insulin levels
All blood samples were obtained via tail bleeding. Plasma
glucose levels were measured directly in the blood using an
Accu-Check Aviva glucose meter (Roche, USA). Plasma
insulin was measured using a commercially available ELISA
kit (Crystal Chem. Inc., IL, USA) after addition of 2 μl EDTA
(0.5 M) to 30-μl blood and centrifugation of the blood sample
(4 °C, 12 min, 3,400 rpm). For the glucose tolerance tests,
glucose (2.5 g/kg body weight) was injected intraperitoneal
(IPGTT) in overnight fasted mice. Glucose and insulin levels
were measured at 0, 15, 30, 60, and 120 min and at 0 and
30 min after glucose administration, respectively.
Quantitative PCR
Total RNA from freshly isolated or cultured pancreatic islets
was extracted with the RNeasy mini kit (QIAGEN). The quan-
tity and quality of the RNA samples were assessed by use of the
Experion RNA StdSens analysis kit (Bio-Rad, USA) and only
RNA samples with a RNA quality indicator value above 5 were
used for further experiments. Complementary DNA was syn-
thesized by using Ready-To-Go You-Prime first-strand beads
(GE Healthcare, UK). Triplicate cDNA samples from each
independent preparation were analyzed by quantitative real-
time polymerase chain reactions (qPCR) in the 7500 real-time
PCR system (Applied Biosystems) using specific TaqMan gene
expression assays for Trpm5 located in the boundary of exons
8–9 and 16–17 (Applied Biosystems; TaqMan assay
Mm00498442_m1 and Mm01129032_m1, respectively). β-
actin and TATA box binding protein were identified as most
stably expressed reference genes by the geNorm analysis [36]
and further used as endogenous controls for accurate normali-
zation of qPCR results (Applied Biosystems, TaqMan assay
Mm_00446973_m1).
Chemicals
Leptin (Sigma-Aldrich) was dissolved at a concentration of
1 mg/ml in 20 mM Tris/HCl (pH 8.0) and further diluted to a
concentration of 0.1 mg/ml in PBS (Invitrogen). Vehicle so-
lution consisted of a 10× dilution of 20 mMTris/HCl (pH 8.0)
in PBS. Insulin (Sigma-Aldrich) was dissolved in diluted
hydrochloric acid (pH=2–3) and further diluted in Milli-Q
water. Diazoxide (Sigma-Aldrich) was dissolved in 0.1 M
NaOH and further diluted in Milli-Q water. Tyrphostin
AG490 (Sigma-Aldrich) was diluted in 100 % EtOH and
further diluted in Milli-Q water.
Cell culture and incubation experiments
Islets from ob /ob micewere isolated and cultured overnight in
culture medium prior to starting the incubation. The next day,
islets from each mouse were divided in two groups and
incubated either in islet culture medium or with 200 ng/ml
leptin added. After a 48-h incubation time, islets were collect-
ed and RNAwas extracted immediately.
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MIN6 cells, a murine pancreaticβ cell line, was cultured in
MIN6 culture medium (Dulbecco’s modified Eagle medium
(Invitrogen) supplemented with 10 % FCS, 100 U/ml penicil-
lin, 100 μg/ml streptomycin, 4 mM Glutamax, β-
mercaptoethanol, and pyruvate) at 5 % CO2/95 % O2. Cells
with a confluence of about 80 % were used for incubation
experiments. After incubation, MIN6 cells were collected and
frozen in liquid nitrogen prior to RNA extraction. MIN6 cells
were kindly provided by Dr. E. Yamato (Osaka University,
Osaka, Japan).
[Ca2+]i measurements
Bath temperature was controlled by a SC-20 dual in-line heater/
cooler (Warner Instruments) and monitored by a TA-29 therm-
istor (Thermometrics) positioned in close vicinity of the islet.
Islets were loaded with 1 μM Fura-2 acetoxymethyl ester
(TefLabs) for 1 h at 37 °C in culture medium. [Ca2+]cyt from
Fura-2 loaded islets was measured monitoring fluorescence
ratio (F350/F380) every second (after correction for background
fluorescence) at 37 °C. [Ca2+]cyt was measured using a mono-
chromator based system consisting of a Polychrome IV mono-
chromator (TILL Photonics) with an additional TILL photonics
photomultiplier, both controlled by Pulse software (HEKA
Elektronik). Standard extracellular solution for Ca2+ imaging
measurements contained (in millimolar) 120 NaCl, 4.8 KCl,
2.5 CaCl2, 1.2 MgCl2, 10 Hepes, at pH 7.4 with NaOH, with
different concentrations of glucose added as indicated.
Data analysis
Origin 7.0 software (OriginLab Corporation, Northhampton,
MA, USA) and Microsoft Excel were used for data analysis.
Data are represented as mean ± SEM, unless mentioned
differently. Normality assumptions were tested with the
Shapiro–Wilk test. Statistical analysis was performed with
the student’s t test, either one-sample (alternative hypoth-
esis: mean≠1) or two-sample, unless mentioned different-
ly. P value <0.05 was considered to represent a significant
difference.
Results
Decreased expression of Trpm5 in pancreatic islets of db /db
and ob /ob mice
Both db /db and ob /ob mice suffer from obesity and dramat-
ically elevated plasma glucose and insulin levels as compared
to age-matched WT mice (see Table 1). Moreover, they show
a severely impaired glucose tolerance (see Fig. 1a, b).
Interestingly, Trpm5 expression was dramatically decreased
in islets from db /db mice at all ages (TaqMan assay located in
a boundary of Trpm5 exons 19–20, WT 1.00±0.25 vs. db /db
0.08±0.02, p =0.006 at 5 weeks; WT 1.00±0.26 vs. db /db
0.02±0.00, p =0.005 at 10 weeks; WT 1.00±0.28 vs. db /db
0.06±0.03, p =0.00008 at 15 weeks; n =5–10 mice per group;
see Fig. 1c). Comparable results were also obtained with a
specific Trpm5 TaqMan assay targeting a boundary of exons
8–9: WT 1.00±0.08 vs. db /db 0.04±0.01, n =3 per group,
p =0.0003 for 10-week-old mice. Similarly to db /db animals,
islets of ob /ob mice also demonstrated downregulation of
Trpm5 expression (WT 1.0±0.49 vs. ob /ob 0.06±0.058,
p =0.007, n =7–8 mice per group, see Fig. 1d). Furthermore,
islets of heterozygous db /+ mice, which do not differ from
WT mice in their metabolic parameters (see Table 1), did not
show alteration of Trpm5 expression when compared with
WT (WT 1.0±0.24 vs. db /+ 1.54±0.05, p =0.21, n =2–3 per
group).
During Fura-2-based Ca2+ imaging, islets from both db /db
and ob /ob mice respond to a stimulus of 10-mM glucose with
an oscillatory increase in the intracellular Ca2+ concentration
([Ca2+]i) (see Fig. 2a), although some islets (4 out of 21 db /db
islets and 5 out of 23 ob /ob islets) responded with a sustained
increase in [Ca2+]i (plateau), a feature that was never detected
in WT islets. Whereas the average [Ca2+]i increase during the
glucose stimulus was comparable in all tested islet groups (see
Fig. 2b), the average frequency of oscillations in db /db and
ob /ob islets was significantly lower than in WT islets and
reached levels observed in Trpm5−/− islets (0.40±0.06 and
0.43±0.04 peaks per min, respectively; see Fig. 2c).
Moreover, they specifically lack fast glucose-induced oscilla-
tions, reminiscent of what is shown for Trpm5−/− islets (see
Fig. 2c). These data suggest that the downregulation of Trpm5
is reflected at the functional level during glucose-induced
Ca2+-signaling in the pancreatic β cell.









WT (n =10) 18.6±0.5 173±7 1.36±0.18
Db /+ 17.8±0.1 151±6 1.4±0.22
Db /db (n =5) 25.2±0.8*** 312±44*** 13.04±0.95***
10 weeks
WT (n =10) 23.8±0.4 155±12 1.51±0.16
Db /db (n =5) 42.6±0.8*** 336±38*** 15.9±0.6***
15 weeks
WT (n =9) 27.7±0.4 134.1±4.4 0.92±0.17
Db /db (n =5) 48.6±0.6*** 259.8±31.1*** 19.05±1.95***
Ob /ob (n =7) 54.3±1.2*** 237.1±32.2* 22.7±0.8***
Comparison of bodyweight, plasma glucose, and plasma insulin levels in
WT, db/db , and ob/ob mice at 5, 10, or 15 weeks of age as indicated.
*p <0.05, **p<0.01, ***p <0.001 versus age-matched WT mice
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Fig. 1 Downregulation of Trpm5
expression in islets from db/db
and ob/ob mice. a , b Plasma
glucose (a) and insulin (b) levels
in WT, db/db, and ob/ob mice
measured during an
intraperitoneal glucose tolerance
test at several time points as
indicated. N=5–10 mice per
group. Asterisk and number sign
indicate significant difference
of WT mice versus db/db
and ob/ob mice, respectively
(**p <0.01, *** <0.001). c , d
QPCR experiments showing
mRNA expression of Trpm5 in
freshly isolated pancreatic islets
from WT and db/db mice at
several ages as indicated (c) or
from WT and ob/ob mice at
15 weeks of age (d). Data are
normalized to the average Trpm5
expression in islets from age-
matched WT mice. N=5–12 per
group, **p <0.01, ***p<0.001
Fig. 2 Glucose-induced Ca2+-signaling in islets from db/db and ob/ob
mice correlates with a loss of TRPM5. a Representative examples of Ca2+-
oscillations in isolated pancreatic islets of db/db, ob/ob , WT, and Trpm5−/−
mice during stimulation with 10 mM glucose. b Average increase in ratio
(F350/F380) in islets from db/db, ob/ob, WT, and Trpm5
−/− islets during
glucose stimulation. One-way ANOVA revealed no difference between the
four groups (overall p=0.1769, n=21–33 per group from 3–7 mice). c
Frequency of oscillations in db/db, ob/ob , WT, and Trpm5−/− islets,
counted as the number of peaks per minute. An increase of 15 % was
considered to be an oscillation, when 100 % is the amplitude between the
baseline and the highest level reached in 10 mM glucose. One-way
ANOVA revealed a difference between the four groups (overall p =
0.00013; n=21–33 per group from 3–7 mice) with the subsequent mean
comparison Bonferroni test showing a difference of WT islets compared to
db/db, ob/ob , and Trpm5−/− islets (*p<0.05, ***p<0.001 vs. WT islets).
Data from WT and Trpm5−/− islets are adapted from [6]
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No effect of dietary compounds on Trpm5 expression
One of the most striking features of db /db and ob /ob mice is
the pronounced obesity, caused by hyperphagia. This increased
food intake leads to higher intake of specific dietary com-
pounds, such as glucose and fat. To investigate whether this
could influence Trpm5 expression levels in pancreatic islets,
we fed normalWTmice during 14weeks with a diet containing
either ≥50 % glucose and ≥12 % oligosaccharides/dextrines (=
high glucose diet) or 30.2% fat (= high fat diet). After 14weeks,
the high fat (but not the high glucose) fed mice had a signifi-
cantly increased bodyweight (normal diet 29.71±0.53 g; high
glucose diet 30.34±1.04 g, p =0.56 vs. normal diet; high fat
diet 46.23±0.67 g, p =5.13−11 vs. normal diet; n =4–6 per
group; see Fig. 3a). There was a tendency in both groups
towards higher plasma glucose levels (normal diet 166.6±
2.8 mg/dl; high glucose diet 177.7±4.4 mg/dl, p =0.042 vs.
normal diet; high fat diet 175.5±4.0mg/dl, p =0.078 vs. normal
diet, n =4–6 per group; see Fig. 3b) and plasma insulin levels
were slightly elevated by both diets (normal diet 0.8±0.07 ng/
ml; high glucose diet 1.36±0.22 ng/ml, p =0.025 vs. normal
diet; high fat diet 2.9±0.37 ng/ml, p =0.00046 vs. normal diet,
n =4–6 per group; see Fig. 3c). However, neither the high
glucose diet (normal diet 1.0±0.07 vs. high glucose diet 0.93
±0.1, p =0.7096; n =4–6 per group) nor the high fat diet
(normal diet 0.99±0.14 vs. high fat diet 0.98±0.18,
p =0.92, n =4–6 per group; see Fig. 3d) altered islet Trpm5
expression, suggesting that dietary compounds are not
responsible for the altered Trpm5 expression in db /db
and ob /ob islets. As the high fat mice also developed obesity,
comparable to that observed in db /db mice, these data
exclude obesity as such being causative of impaired Trpm5
expression.
Leptin treatment converts diabetic phenotype and rescues
Trpm5 expression in ob /ob mice
Five-week-old ob /ob mice were daily injected with a dose of
1 mg/kg bodyweight leptin i.p. during 5 weeks and compared
to ob /ob mice that received daily vehicle injections. Leptin
injections decreased the daily food intake per mouse (vehicle-
injected 5.83±0.05 vs. leptin-injected 3.31±0.19 g/day/
mouse). During the course of the experiment, the bodyweight
of the vehicle-treated group increased much faster as com-
pared to the leptin-injected group, with a statistically signifi-
cant difference starting from day 8, reaching bodyweights of
44.5±1.7 g for the vehicle-injected group and 35.6±1.0 g for
the leptin-injected group after 36 days (n =10 per group,
p =0.000663, see also Fig. 4a). After 5 weeks, both plasma
glucose levels (vehicle-injected 188.2±9.6 mg/dl vs. leptin-
Fig. 3 No effect of dietary compounds on Trpm5 expression. a–c
Metabolic phenotype of WT mice that received either a high glucose diet
(containing ≥50 % glucose and ≥12+ oligosaccharides/dextrines) or a
high fat diet (containing 30.2 % fat) during 14 weeks. a Bodyweight in
WT mice that had received a normal, a high glucose, or a high fat diet
during 14 weeks. b , c Average plasma glucose (b) and insulin levels (c)
over the course of the experiment in mice receiving a normal, a high
glucose, or a high fat diet during 14 weeks. d Islet Trpm5 expression
levels after 14 weeks of diet. Trpm5 expression is normalized to the
average Trpm5 expression in islets from age-matched mice that received
a normal diet. N=4–6 mice per group, *p <0.05, ***p <0.001 vs. WT
mice on a normal diet
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injected 152.2±7.7 mg/dl; p =0.0098, n =10 per group) and
plasma insulin levels (vehicle-injected 16.2±2.0 ng/ml vs.
leptin-injected 5.7±1.2 ng/ml; p =0.00025, n =10 per group)
were dramatically decreased due to leptin treatment (see
Fig. 4b, c). Moreover, the leptin treatment restored glucose
tolerance in ob /ob mice (Fig. 5). Interestingly, islet Trpm5
expression in islets of leptin-treated mice was upregulated as
compared to islets of vehicle-injected mice (vehicle 0.96±
0.25 vs. leptin 6.52±0.61; p =2.1−6, n =7 per group). These
data imply that downregulation of Trpm5 expression in islets
from ob /ob and db /db mice results from the disruption of the
leptin pathway and/or the consequent diabetic phenotype.
No additional effect of leptin on Trpm5 expression
when plasma insulin levels are equal
between leptin- and vehicle-injected ob /ob mice
In order to investigate whether the recovery of the leptin path-
way (without altering the metabolic phenotype) would be suf-
ficient to upregulate Trpm5 expression, we injected 9-week-old
ob /ob mice for 2 days with either 1 mg leptin per kilogram
bodyweight or vehicle. Since leptin will have a dramatic and
immediate effect on food intake and consequently on the met-
abolic phenotype, animals were divided in two groups as
follows: one group of mice had free access to food for the
whole duration of the experiment (Fig. 6a), whereas a second
group was put on food restriction, meaning that they received
3 g of food per day and were fasted overnight during the last
night before islet isolation (Fig. 6b). Bodyweight was not
altered by this short period of leptin treatment, neither in the
fed ad libitum group (vehicle-injected 44.1±1.7 g vs. leptin-
injected 42.7±1.1 g; p =0.52, n =4 mice per group) nor in the
food restriction group (vehicle-injected 41.0±0.7 g vs. leptin-
injected 39.2±1.5 g; p =0.33, n =4 mice per group). Also,
plasma glucose levels did not change after 2 days of leptin
treatment for both groups: vehicle-injected 245.5±68.2 mg/dl
versus leptin-injected 167.5±4.9 mg/dl; p =0.30, n =4mice per
group for the fed ad libitum mice and vehicle-injected 179±
18 mg/dl versus leptin-injected 155±17 mg/dl; p =0.38, n =4
mice per group for the mice put on food restriction. However,
plasma insulin was dramatically decreased by leptin treatment
in the fed ad libitum mice (vehicle-injected 16.9±1.4 ng/ml vs.
leptin-injected 6.2±1.0 ng/ml; p =0.0008, n =4 mice per
group). In contrast, the mice that were on food restriction
displayed normal insulin levels (4.4±1.6 ng/ml vs. 2.7±
1.2 ng/ml, respectively, p =0.41, n =4 mice per group).
Interestingly, Trpm5 was upregulated by leptin treatment in
mice that had free access to food (vehicle-injected 0.96±0.43
vs. leptin-injected 3.65±0.53; p =0.0092, n =4 mice per group)
but not in mice that were on food restriction (vehicle-injected
0.95±0.36 vs. leptin-injected 1.08±0.31, p =0.86, n =4 mice
per group). These data strongly suggest that plasma insulin
levels are a critical factor in the regulation of islet Trpm5
expression.
Fig. 4 Leptin treatment of
leptin-deficient ob/ob mice
causes a reversal of the diabetic
phenotype and an upregulation of
islet Trpm5 expression.
Metabolic phenotype of ob /ob
mice that were injected either with
1 mg leptin/kg bodyweight or
with vehicle during 5 weeks. a–c
Bodyweight (a), plasma glucose
(b), and plasma insulin levels (c)
were measured on a daily
(bodyweight) or a weekly (plasma
glucose and insulin) basis. There
was a statistically significant
difference of bodyweight between
the two groups starting from day
8. d Trpm5 mRNA expression in
freshly isolated pancreatic islets
from vehicle- and leptin-injected
ob/ob mice after 5 weeks of
treatment. Data were normalized
to the average Trpm5 expression
in islets from vehicle-injected
mice. N =10 mice per group,
**p <0.01, ***p<0.001
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Insulin levels are important for downregulation of Trpm5
We incubated the insulinoma cell line MIN6 cells with several
factors altered in these mouse models for type 2 diabetes. First
of all, both mouse strains suffer from a defect in the leptin
signaling pathway. Activation of the leptin pathway in MIN6
cells by incubation with 200 ng/ml leptin for 48 h had
no influence on Trpm5 expression (control 1.00±0.05 vs.
leptin 1.17±0.13, n =3 per group, p =0.22; Fig. 7a).
Furthermore, disrupting leptin signaling by adding the com-
pound Tyrphostin AG490 to the incubation medium for
1 week had no effect on Trpm5 expression in MIN6 cells
(leptin 1.0±0.08 vs. leptin+AG490 0.85±0.09, n =3 per
group, p =0.279). Similarly, recovery of the leptin pathway
in ob /ob islets by incubation with 200 ng/ml leptin for 48 h
had no influence on Trpm5 expression (islet Trpm5 expres-
sion 1.27±0.22 vs. control, n =4, one-paired t test p =0.30;
Fig. 7b, c). These data strongly suggest that the disrupted
leptin pathway is not the cause of the downregulation of
Trpm5 .
Second, db /db and ob /ob mice suffer from high plasma
glucose levels. However, incubation of MIN6 cells with
25 mM glucose did not alter Trpm5 expression as compared
to expression in cells incubated in 5.5 mM glucose (5.5 mM
glucose+250 μM diazoxide 1.0±0.0 vs. 25 mM glucose+
250 μM diazoxide 1.13±0.12, p =0.39, n =3–6 per group;
Fig. 7d), implying no influence of high glucose levels on
Trpm5 expression.
Finally, diabetic db /db and ob /ob mice display elevated
plasma insulin levels. Incubation of MIN6 cells for 1 week
with increasing concentrations of insulin dose-dependently
decreased Trpm5 expression (control 1.0±0.0; 10 nM insulin
0.74±0.05, p =0.0082; 100 nM insulin 0.61±0.05, p =
0.00027; n =4–7 per group; Fig. 7e), indicating that high
plasma insulin levels are indispensable for the downregulation
of Trpm5 in pancreatic islets from diabetic mice.
Discussion
TRPM5was previously identified as a critical component in the
electrical activity of the pancreatic β cell and in glucose-
induced insulin release [6]. Since Trpm5−/− mice show a pre-
diabetic phenotype, it is conceivable that mutations or altered
expression patterns of Trpm5 are involved in the pathogenesis
of type 2 diabetes mellitus. Expression of Trpm5 in the small
intestine has been shown to be negatively correlated with blood
glucose concentrations in type 2 diabetic patients [38].
Moreover, genetic variation of Trpm5 is shown to be associated
with pre-diabetic phenotypes in a population of European an-
cestry [13]. Although the functional relevance of these muta-
tions remains to be shown, these data strongly suggest a link
between TRPM5 and type 2 diabetes. In this study, we provide
evidence that elevated plasma insulin levels are important for
the downregulation of Trpm5 expression in pancreatic islets
from animal models with impaired leptin signaling.
Trpm5 mRNA expression was almost 20-fold downregu-
lated in islets from db /db and ob /ob mice, two mouse models
of type 2 diabetes. Both mouse models suffer from a defect in
leptin-signaling, resulting in hyperphagia, obesity, hyperinsu-
linism, hyperglycemia, and diabetes [5, 18]. We systematical-
ly tested whether any of these factors underlies the downreg-
ulation of Trpm5 . Interestingly, the glucose-induced Ca2+-
signaling in islets from db /db and ob /ob mice correlated well
with a loss of TRPM5. Previous studies from our laboratory
show that Trpm5−/− islets display a reduced frequency of
oscillations in Ca2+ and Vm, specifically due to a lack of fast
oscillations [6]. During glucose stimulation, db /db and ob /ob
islets showed a frequency of Ca2+ oscillations comparable to
Trpm5−/− islets and significantly lower than oscillations in
WT islets. They never showed simple fast glucose-induced
oscillations as detected in a population of WT islets. Irregular
Ca2+ oscillations and, more specifically, a lack of fast
Fig. 5 IPGTT in ob/ob mice injected during 5 weeks with leptin or
vehicle. a Plasma glucose levels in ob/ob mice that were injected with
leptin or vehicle during 5 weeks. Mice received an i.p. injection of 2.5 g
glucose/kg bodyweight and plasma glucose was measured at several time
points as indicated. b Plasma insulin levels after overnight fasting and
30 min after i.p. glucose injection of 2.5 g glucose/kg bodyweight. N =10
mice per group, *p<0.05, ***p <0.001
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oscillations in db /db and ob /ob islets had been shown before
[31, 32]. These results suggest that islets from db /db and ob /
ob mice display reduced TRPM5 channel activity, consistent
with the downregulation of Trpm5 mRNA expression.
As mentioned above, genetic variation of Trpm5 has been
shown to associate with pre-diabetic phenotypes [13].
Notably, these mutations were all found in intron sequences,
suggesting alternative splicing. Using Trpm5 -specific
TaqMan assays located in distinct exon boundaries (8–9 and
19–20), we did not find any evidence for the presence of
alternative splice variants of Trpm5 in the islets of db /db
mice. Another possible explanation is that some of these
mutations might be a part of cis-regulatory elements involved
in transcriptional regulation of Trpm5 . It has been recently
shown that transcriptional regulation of the cystic fibrosis
transmembrane conductance regulator (CFTR), an epithelial
chloride channel, depends on the cis-regulatory elements lo-
cated in intron 11 ofCFTR (100 kb distal to the promoter) [12,
26]. These critical cis-acting elements recruit multiple tran-
scription factors that tune the tissue-specific gene expression.
Both db /db and ob /ob mice suffer from hyperphagia that
leads to obesity and consequently to diabetes. This increased
food provisions results in higher intake of certain compounds
such as sugars and fat, suggesting that these food constituents
might be responsible for the downregulation of Trpm5 .
However, neither a high glucose nor a high fat diet for
14 weeks had any influence on Trpm5 expression in pancre-
atic islets after 14 weeks. As the mice fed with a high fat diet
showed a marked obesity, comparable to that detected in db /
db mice, we can also exclude obesity as being responsible for
Trpm5 downregulation. Although both diets slightly elevated
plasma glucose and insulin levels, the metabolic phenotype
Fig. 6 Effect of leptin injection
on islet Trpm5 expression and
circulating insulin levels in
control-fed and food-restricted
mice. Bodyweight, plasma
glucose, plasma insulin, and islet
Trpm5 expression in ob/ob mice
that were injected for 2 days with
either 1 mg leptin/kg bodyweight
or vehicle. Mice were divided in
two groups: they had either free
access to food during the course
of the experiment (a) or were put
on food restriction (b), meaning
that they received 3 g of food per
mouse per day and were fasted
overnight during the last night
before islet isolation. Trpm5
expression in islets from leptin-
injected mice was normalized to
the average Trpm5 expression in
islets from vehicle-injected mice
that had followed the same food
protocol. N =4 mice per group,
**p <0.01, ***p<0.001
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detected in these mice was much less severe as compared to
db /db and ob /ob mice.
Leptin has several effects on glucose homeostasis in the
body. It reduces hepatic glucose production, increases glucose
uptake from skeletal muscle cells, and reduces insulin synthesis
and release from β cells [1, 33, 37]. Insulin released from the β
cell increases secretion of leptin from adipose tissue that in turn
will reduce insulin secretion. This so called adipo-insular axis is
proposed to be disturbed in type 2 diabetes due to leptin
resistance of the β cell, leading to increased insulin release
[20, 37]. Interestingly, leptin has also been shown to alter the
expression of several genes in pancreatic β cells [34]. The
proinsulin gene and protein phosphatase 1 gene are repressed
by leptin-dependent pathways, whereas the gene encoding the
suppressor of cytokine signaling 3 protein is a leptin-induced
gene in pancreatic β cells. Thus, it is conceivable that leptin
signaling might be directly involved in the regulation of Trpm5
expression. Reconstitution of leptin signaling by i.p. injections
in ob /ob mice recovered Trpm5 expression both after long-
term (5 weeks) and short-term (2 days) treatment. After long-
term treatment with leptin, ob /ob mice display normal (i.e.,
comparable to WT) bodyweight, plasma glucose, and insulin
levels and a normal IPGTT profile, as expected [28]. On the
other hand, 2 days of leptin treatment not only normalized
plasma insulin levels but also increased the Trpm5 expression
level, indicating that either leptin signaling as well as plasma
insulin levels regulate Trpm5 expression. In contrast, incuba-
tion of either MIN6 or isolated ob /ob islets with leptin had no
influence on Trpm5 expression. Similarly, disruption of leptin
signaling in MIN6 cells had no effect on Trpm5 expression.
Strikingly, when leptin-treated and -untreated ob /ob mice were
placed on a food-restricted diet for 2 days, resulting in signif-
icantly decreased insulin levels in both groups, there was no
additional effect of leptin treatment on Trpm5 expression.
Thus, all these data contradict with a direct role of leptin
signaling in Trpm5 gene regulation.
Hyperglycemia and hyperinsulinism lead to altered expres-
sion patterns of several genes in β cells [15–17, 21, 24].
Whereas incubation of MIN6 cells with glucose did not
change the expression pattern of Trpm5 , insulin dose-
dependently decreased Trpm5 expression in MIN6 cells.
These data are consistent with results obtained from leptin-
Fig. 7 Insulin downregulates Trpm5 expression in Min6 cells. a , b
Trpm5 expression in the insulinoma cell line MIN6 incubated for 1 week
with 200 ng/ml leptin (a) or with 200 ng/ml leptin+30 μM Tyrphostin
AG490 (b). Control medium contained either no leptin (a) or 200 ng/ml
leptin (b). Expressionwas normalized to Trpm5 expression inMIN6 cells
incubated in control medium. N =3 per group. c Trpm5 expression in ob/
ob islets incubated with 200 ng/ml leptin for 48 h. Expression was
normalized to expression in islets from the same animal incubated in
control medium. N =4 per group, p =0.149 (one-paired t test). d Trpm5
expression in MIN6 cells incubated for 1 week with 25 mM glucose+
250 μM diazoxide. Expression was normalized to Trpm5 expression in
MIN6 cells incubated in control medium containing 5.5 mM glucose+
250 μMdiazoxide. N=3–7 per group. e Trpm5 expression inMIN6 cells
after incubation with either 10 or 100 nM insulin during 1 week. The
incubation medium contained 5.5 mM glucose and expression was nor-
malized to Trpm5 expression in MIN6 cells incubated in control medium
without insulin. N=7 per group, **p <0.01, ***p <0.001
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injected ob /ob mice. Taken together, our data indicate that the
elevated plasma insulin level in db /db and ob /ob mice is
major responsible for the downregulation of Trpm5 . It is clear
that plasma insulin levels have to be substantially elevated to
cause downregulation of Trpm5 , as mice fed with a high fat
diet (where plasma insulin levels were only slightly elevated
to 0.5nM) showed no alteration in Trpm5 levels. Moreover, it
might be difficult to explain the discrepancy between in vitro
insulin concentrations (10–100nM) needed to obtain down-
regulation of Trpm5 and concentrations of plasma insulin
levels measured in vivo in db /db and ob /ob mice (2–
4 nM). However, it is clear that plasma insulin levels do
not indicate actual insulin levels sensed by the β cell in
its micro-environment. Moreover, the time scales of the
performed experiments differed (mice of 5, 10, and
15 weeks old vs. 1 week incubation of MIN6 cells with
insulin), and it is well accepted that insulin might trigger
events on different time scales [16]. An immediate effect
of insulin is proposed to be the opening of KATP channels
by activation of PI3kinase and production of PI(3,4,5)P3
[14]. Whereas this is triggered in seconds or only a few
minutes, events such as gene transcription and translation
require several minutes to hours and even longer when
protein synthesis of transcription factors is involved [16].
What could be the physiological relevance of insulin alter-
ing expression level of the Trpm5 gene? The dynamics of
insulin secretion could partly explain this phenomenon [16].
The autocrine effect of secreted insulin on its own secretion is
still a matter of debate and both negative and positive feed-
back mechanisms are reported [16, 17]. Indeed, insulin is
released in a pulsatile manner, a feature believed to be impor-
tant to maintain insulin sensitivity not only in peripheral cells
but also in β cells. Interestingly, impairment of pulsatile
insulin release is an early marker for β cell dysfunction in
type 2 diabetes and is even detected in relatives of patients
with type 2 diabetes [25, 29]. Steadily elevated plasma insulin
levels are believed to cause a negative feedback on insulin
secretion [29]. In this regard, the elevated plasma insulin
levels detected in db /db and ob /ob mice might hamper
its own secretion partly by downregulation of Trpm5 , a
positive regulator of insulin release. Thus, insulin-
dependent downregulation of Trpm5 expression may rep-
resent a compensatory mechanism in order to prevent
excessive insulin secretion and protect against hyperin-
sulinism. How insulin would downregulate TRPM5 ex-
pression is still unclear. Possible mechanisms include a
direct influence of insulin-induced intracellular signaling
on Trpm5 promoter activity, through cis- and trans-acting
elements [24]. Alternatively, insulin regulates the expression
of several microRNA’s [8]. However, the putative Trpm5
promoter region does not contain insulin-responsive elements,
nor have any specific miRNA’s been identified which interact
with the Trpm5 gene.
Acknowledgment The authors are supported by the FWO Vlaanderen
(G.0761.10N, ASP/11-Griet Jacobs, G.0596.12, G.0565.07), the IUAP
program from the Belgian Federal Government (P7/13), and the
KULeuven “Bijzonder Onderzoeksfonds” (STRT1/09/046, GOA
2009/07, EF/95/010, and TRPLe).
Conflict of interest The authors have no competing financial interests
to declare.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Anubhuti, Arora S (2008) Leptin and its metabolic interactions: an
update. Diabetes Obes Metab 10:973–993
2. Ashcroft F, Rorsman P (2004) Type 2 diabetes mellitus: not quite
exciting enough? Hum Mol Genet 13 Spec No 1:R21-31
3. Brixel LR, Monteilh-Zoller MK, Ingenbrandt CS, Fleig A, Penner R,
Enklaar T, Zabel BU, Prawitt D (2010) TRPM5 regulates glucose-
stimulated insulin secretion. Pflugers Arch 460:69–76
4. Chen H, Charlat O, Tartaglia LA,Woolf EA,WengX, Ellis SJ, Lakey
ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI,
Morgenstern JP (1996) Evidence that the diabetes gene encodes the
leptin receptor: identification of a mutation in the leptin receptor gene
in db/db mice. Cell 84:491–495
5. Coleman DL (1978) Obese and diabetes: two mutant genes causing
diabetes-obesity syndromes in mice. Diabetologia 14:141–148
6. Colsoul B, Schraenen A, Lemaire K, Quintens R, Van Lommel L,
Segal A, Owsianik G, Talavera K, Voets T, Margolskee RF,
Kokrashvili Z, Gilon P, Nilius B, Schuit FC, Vennekens R (2010)
Loss of high-frequency glucose-induced Ca2+ oscillations in pancre-
atic islets correlates with impaired glucose tolerance in Trpm5−/−
mice. Proc Natl Acad Sci USA 107:5208–5213
7. Colsoul B, Vennekens R, Nilius B (2011) Transient receptor potential
cation channels in pancreatic beta cells. Rev Physiol Biochem
Pharmacol 161:87–110
8. Dumortier O, Hinault C, Van Obberghen E (2013) MicroRNAs
and metabolism crosstalk in energy homeostasis. Cell Metab
18:312–324
9. Fradin D, Bougneres P (2011) T2DM: why epigenetics? J Nutr
Metab 2011:647514
10. Gees M, Colsoul B, Nilius B (2011) The role of transient receptor
potential cation channels in Ca2+ signalingCold Spring Harb
Perspect Biol. United States, pp. a003962
11. Hofmann T, Chubanov V, Gudermann T, Montell C (2003) TRPM5
is a voltage-modulated and Ca(2+)-activated monovalent selective
cation channel. Curr Biol 13:1153–1158
12. Kerschner JL, Harris A (2012) Transcriptional networks driving
enhancer function in the CFTR gene. Biochem J 446:203–212
13. Ketterer C, Mussig K, Heni M, Dudziak K, Randrianarisoa E,
Wagner R, Machicao F, Stefan N, Holst JJ, Fritsche A, Haring HU,
Staiger H (2011) Genetic variation within the TRPM5 locus associ-
ates with pre-diabetic phenotypes in subjects at increased risk for type
2 diabetes. Metabolism 60:1325–1333
14. Khan FA, Goforth PB, Zhang M, Satin LS (2001) Insulin
activates ATP-sensitive K(+) channels in pancreatic beta-cells through
a phosphatidylinositol 3-kinase-dependent pathway. Diabetes 50:
2192–2198
15. Leibiger B, Leibiger IB, Moede T, Kemper S, Kulkarni RN, Kahn
CR, de Vargas LM, Berggren PO (2001) Selective insulin signaling
620 Pflugers Arch - Eur J Physiol (2014) 466:611–621
through A and B insulin receptors regulates transcription of insulin
and glucokinase genes in pancreatic beta cells. Mol Cell 7:559–570
16. Leibiger IB, Leibiger B, Berggren PO (2002) Insulin feedback action
on pancreatic beta-cell function. FEBS Lett 532:1–6
17. Leibiger IB, Leibiger B, Berggren PO (2008) Insulin signaling in the
pancreatic beta-cell. Annu Rev Nutr 28:233–251
18. Lindstrom P (2007) The physiology of obese-hyperglycemic mice
[ob/ob mice]. ScientificWorldJournal 7:666–685
19. Ling C, Groop L (2009) Epigenetics: a molecular link be-
tween environmental factors and type 2 diabetes. Diabetes 58:2718–
2725
20. Marroqui L, Gonzalez A, Neco P, Caballero-Garrido E, Vieira E,
Ripoll C, Nadal A, Quesada I (2012) Role of leptin in the pancreatic
beta-cell: effects and signaling pathways. J Mol Endocrinol 49:R9–
R17
21. Martens GA, Pipeleers D (2009) Glucose, regulator of survival and
phenotype of pancreatic beta cells. Vitam Horm 80:507–539
22. Nilius B, Owsianik G, Voets T, Peters JA (2007) Transient receptor
potential cation channels in disease. Physiol Rev 87:165–217
23. Nilius B, Owsianik G (2010) Transient receptor potential channelop-
athies. Pflugers Arch 460:437–450
24. O’Brien RM, Granner DK (1996) Regulation of gene expression by
insulin. Physiol Rev 76:1109–1161
25. O’Rahilly S, Turner RC, Matthews DR (1988) Impaired pulsatile
secretion of insulin in relatives of patients with non-insulin-
dependent diabetes. N Engl J Med 318:1225–1230
26. Ott CJ, Bischof JM, Unti KM, Gillen AE, Leir SH, Harris A (2012)
Nucleosome occupancy reveals regulatory elements of the CFTR
promoter. Nucleic Acids Res 40:625–637
27. Pedersen SF, Owsianik G, Nilius B (2005) TRP channels: an over-
view. Cell Calcium 38:233–252
28. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters
D, Boone T, Collins F (1995) Effects of the obese gene
product on body weight regulation in ob/ob mice. Science 269:
540–543
29. Porksen N (2002) The in vivo regulation of pulsatile insulin secre-
tion. Diabetologia 45:3–20
30. Prawitt D, Monteilh-Zoller MK, Brixel L, Spangenberg C, Zabel B,
Fleig A, Penner R (2003) TRPM5 is a transient Ca2+-activated cation
channel responding to rapid changes in [Ca2+]i. Proc Natl Acad Sci
USA 100:15166–15171
31. Ravier MA, Sehlin J, Henquin JC (2002) Disorganization of cyto-
plasmic Ca(2+) oscillations and pulsatile insulin secretion in islets
from ob/ob mice. Diabetologia 45:1154–1163
32. Roe MW, Philipson LH, Frangakis CJ, Kuznetsov A, Mertz RJ,
Lancaster ME, Spencer B, Worley JF 3rd, Dukes ID (1994) Defective
glucose-dependent endoplasmic reticulum Ca2+ sequestration in diabet-
ic mouse islets of Langerhans. J Biol Chem 269:18279–18282
33. Seufert J, Kieffer TJ, Habener JF (1999) Leptin inhibits insulin gene
transcription and reverses hyperinsulinemia in leptin-deficient ob/ob
mice. Proc Natl Acad Sci USA 96:674–679
34. Seufert J (2004) Leptin effects on pancreatic beta-cell gene expres-
sion and function. Diabetes 53(Suppl 1):S152–S158
35. Slomko H, Heo HJ, Einstein FH (2012) Minireview: epigenetics of
obesity and diabetes in humans. Endocrinology 153:1025–1030
36. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De
Paepe A, Speleman F (2002) Accurate normalization of real-time
quantitative RT-PCR data by geometric averaging ofmultiple internal
control genes. Genome Biol 3:RESEARCH0034
37. Yildiz BO, Haznedaroglu IC (2006) Rethinking leptin and insulin
action: therapeutic opportunities for diabetes. Int J Biochem Cell Biol
38:820–830
38. Young RL, Sutherland K, Pezos N, Brierley SM, Horowitz M,
Rayner CK, Blackshaw LA (2009) Expression of taste molecules in
the upper gastrointestinal tract in humans with and without type 2
diabetes. Gut 58:337–346
Pflugers Arch - Eur J Physiol (2014) 466:611–621 621
